Research News

Metformin is backed as first line therapy for type 2 diabetes

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2236 (Published 20 April 2016) Cite this as: BMJ 2016;353:i2236
  1. Jacqui Wise
  1. London

The use of metformin as first line therapy for type 2 diabetes has been supported by a comprehensive systematic review and meta-analysis, given its relative safety and its beneficial effects on haemoglobin A1c, weight, and cardiovascular mortality.1

The US research, published in the Annals of Internal Medicine, included 179 trials and 25 observational studies of head to head monotherapy or …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe